iRegene Therapeutics Raises 210M Yuan in Series C1 for AI-Powered Cell Therapy Platform
iRegene Therapeutics has secured 210 million yuan (approximately $29 million) in a Series C1 funding round. The company plans to utilize these funds to further develop its AI-powered platform, which focuses on creating universal cell therapies for age-related diseases. AI
IMPACT Accelerates development of AI-driven therapies for age-related diseases, potentially improving treatment outcomes.